Related Experiment Video
Updated: May 6, 2026
08:49
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
1.4K
Natriuretic peptide-guided heart failure management.
Richard Troughton1, G Michael Felker, James L Januzzi
1Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
European Heart Journal
|November 13, 2013
Summary
Natriuretic peptides, like B-type natriuretic peptide (BNP) and NT-proBNP, can guide heart failure (HF) therapy. Optimizing treatment based on these biomarkers and achieving suppression below thresholds improves patient outcomes.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Management
Background:
- Natriuretic peptides (NPs), including B-type natriuretic peptide (BNP) and NT-proBNP, are crucial for diagnosing and determining prognosis in heart failure (HF).
- Therapeutic interventions for HF lead to parallel changes in BNP and NT-proBNP levels, reflecting treatment benefits.
Purpose of the Study:
- To explore the concept of using natriuretic peptides as a guide for intensifying heart failure care.
- To assess the impact of optimizing therapy and achieving NP suppression on patient outcomes.
Main Methods:
- Reviewing past studies on biomarker-guided HF therapy.
- Analyzing the dynamic changes in BNP and NT-proBNP in response to HF therapies.
- Evaluating the combination of guideline-directed medical therapy (GDMT) and NP suppression.
Main Results:
- Studies combining therapy optimization and NP suppression below prognostic thresholds show superior outcomes.
- This integrated approach has been observed to be well-tolerated by patients.
- US HF guidelines now recommend natriuretic peptide-guided therapy for achieving GDMT (Class IIa) and potentially improving outcomes (Class IIb).
Conclusions:
- Natriuretic peptide-guided HF therapy represents a novel approach to managing heart failure.
- Further clinical trial data is anticipated to inform international guidelines, such as those from the European Society of Cardiology.
- This strategy holds promise for improving patient outcomes in heart failure management.
Related Concept Videos
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:30Heart Failure VII: Nursing Interventions
807
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
807
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:28Mitral Regurgitation IV: Nursing Management
606
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
606
01:22Heart Failure Drugs: Diuretics
1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K